$1m refund for INOVIQ’s cancer research
INOVIQ (ASX:IIQ) has received a $1.018m refund under the Australian Government’s Research & Development (R&D) Tax Incentive program for the fiscal year ending 30 June 2024. The refund reflects $2.7m spent on eligible R&D activities, excluding certain overseas expenditures. The Melbourne-based company specialises in developing diagnostics and therapeutics for cancer. Among its advancements is the […]
$1m refund for INOVIQ’s cancer research Read More »